BioSpace News Archive

MD Anderson discovery provides new druggable targets to test against lethal brain tumor

A Phase III trial compared Sanofi’s Soliqua/Suliqua to other GLP-1 receptor agonists (GLP-1 RA), with Soliqua showing a superior decrease of average blood sugar level (HbA1c) after 26 weeks.

Trial data showed a two-week course delayed the onset of diabetes by as much as two years in clinical patients.

Company Created ACCEL (Access to Excellent Care for Sickle Cell Patients Pilot Program) to Accelerate Development of Innovative Healthcare Programs for Sickle Cell Community

Nationally Recognized Non-Profit Hosts Ribbon Cutting Ceremony to Celebrate 75 New Frederick County Jobs

Zomedica Pharmaceuticals Corp. announced that it has completed its second tranche closing of Series 1 Preferred Shares with the issuance of 7 Series 1 Preferred Shares to an accredited investor under a private placement at a purchase price of $1,000,000 per Series 1 Preferred Share for a total purchase price of $7,000,000.

Approximately 9,000 employees participate in volunteer activities to update schools and community centers all over the world benefitting more than 70,000 students and 50,000 community members

An article published in Experimental Biology and Medicine details a new therapeutic strategy for obesity and type 2 diabetes.

Evotec SE announced that the company has entered into a five-year partnership with the Bill & Melinda Gates Foundation to discover new treatment regimens that better address tuberculosis (“TB”), a severe global health burden and one of the leading causes of death due to infectious diseases worldwide.

Government agencies in the United States and U.K. are scrutinizing Roche’s planned acquisition of the gene therapy company.